About LivaNova PLC (NASDAQ:LIVN)
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company's segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.
Industry, Sector and Symbol:
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: N/A
- Sector: Medical Equipment, Supplies & Distribution - NEC
- Symbol: NASDAQ:LIVN
- CUSIP: N/A
- Web: www.livanova.comhome.action
- Debt-to-Equity Ratio: 0.04%
- Current Ratio: 2.03%
- Quick Ratio: 1.42%
Sales & Book Value:
- Trailing P/E Ratio: 23.64
- Forward P/E Ratio: 25.32
- P/E Growth: 2.46
- Annual Sales: $1.2139 billion
- Price / Sales: 3.35
- Cash Flow: $5.57 per share
- Price / Cash: 15.15
- Book Value: $39.71 per share
- Price / Book: 2.12
- Trailing EPS: $3.75
- Net Income: ($62,780,000.00)
- Net Margins: 4.63%
- Return on Equity: 9.33%
- Return on Assets: 6.82%
- Employees: 4,500
- Outstanding Shares: 48,210,000
Frequently Asked Questions for LivaNova PLC (NASDAQ:LIVN)
What is LivaNova PLC's stock symbol?
LivaNova PLC trades on the NASDAQ under the ticker symbol "LIVN."
How were LivaNova PLC's earnings last quarter?
LivaNova PLC (NASDAQ:LIVN) posted its quarterly earnings results on Thursday, November, 2nd. The company reported $0.93 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.76 by $0.17. The business earned $309.70 million during the quarter, compared to the consensus estimate of $301.22 million. LivaNova PLC had a net margin of 4.63% and a return on equity of 9.33%. The company's quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.78 earnings per share. View LivaNova PLC's Earnings History.
When will LivaNova PLC make its next earnings announcement?
What guidance has LivaNova PLC issued on next quarter's earnings?
LivaNova PLC issued an update on its FY17 earnings guidance on Thursday, November, 2nd. The company provided earnings per share guidance of $3.30-3.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.24.
Where is LivaNova PLC's stock going? Where will LivaNova PLC's stock price be in 2017?
7 brokers have issued 12 month price objectives for LivaNova PLC's stock. Their predictions range from $50.00 to $91.00. On average, they expect LivaNova PLC's stock price to reach $76.83 in the next twelve months. View Analyst Ratings for LivaNova PLC.
What are Wall Street analysts saying about LivaNova PLC stock?
Here are some recent quotes from research analysts about LivaNova PLC stock:
- 1. Canaccord Genuity analysts commented, "We stay HOLD rated on LIVN coming out of constructive meetings with management on the road last week. We continue to believe the firm possesses intriguing long-term growth initiatives –in transcatheter mitral valve replacement (TMVR), heart failure (HF) and treatment-resistant depression (TRD) – but anticipate these segments will take several years to materialize and likely require additional M&A and material R&D spending before either the TMVR or HF initiatives could potentially contribute to LIVN’s top- and bottom-line growth profiles. That said, we sensed incrementally stronger conviction from management regarding both robust GM expansion potential as well as low-DD revenue growth from the emerging markets (ROW) business. Taken together, we management seems confident it can deliver merger integration cost synergies that the think these drivers could help the firm hit or exceed its guidance in 4Q:17." (11/14/2017)
- 2. According to Zacks Investment Research, "LivaNova PLC is a medical technology company which focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company's operating units consists of Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. LivaNova PLC, formerly known as Cyberonics, Inc., is based in London, United Kingdom. " (11/9/2017)
- 3. Needham & Company LLC analysts commented, "LIVN announced that it is exploring strategic options for its low growth and low margin CRM business. This shouldn’t come as a huge surprise since management had previously hinted a potential sale of the CRM business. We think a CRM sale would increase LIVN’s revenue growth; the EPS impact hinges on price, CRM margins, and use of proceeds. We think a sale would be neutral to slightly dilutive if the proceeds were used for share repurchases and/or debt repayment though we note that there would likely be near-term hit to EPS between when the sale is announced and when LIVN is able to deploy the proceeds to offset any dilution." (9/14/2017)
- 4. BTIG Research analysts commented, "Last week, while we were at our Snowbird conference, LIVN reported Q4 results and released initial FY17 guidance. Once again, we are lowering our estimates for LIVN. While shares are inexpensive, we do not see how it will grow in the future unless major M&A or R&D efforts take place, moving LIVN into new markets. Given most of LIVN’s markets are flat to declining, we would be inclined to wait for the company to show intentions to enter new markets before recommending shares. We don’t expect an inflection point on cardiac surgery anytime soon and while new iterations in Neuromod may pad growth in 2H17, we think the lower end of the 1-3% revenue growth guidance would be a good achievement. There remain considerable areas of opportunity on the synergy side, which should support EPS growth. With the first innings of physical integration behind them, we think the co. is in a better position to focus on more sizeable areas of savings such as purchasing/direct procurement. However, we think the lack of revenue growth is more important than synergies and we reiterate our Neutral rating." (3/10/2017)
Who are some of LivaNova PLC's key competitors?
Some companies that are related to LivaNova PLC include Steris Plc (STE), West Pharmaceutical Services (WST), Hill-Rom Holdings (HRC), DexCom (DXCM), VWR Corporation (VWR), Integra LifeSciences Holdings Corporation (IART), Globus Medical (GMED), Neogen Corporation (NEOG), NuVasive (NUVA), Inogen (INGN), Nevro Corp. (NVRO), Halyard Health (HYH), CONMED Corporation (CNMD), MiMedx Group (MDXG), Given Imaging (GIVN), Orthofix International N.V. (OFIX), OraSure Technologies (OSUR) and Intersect ENT (XENT).
Who owns LivaNova PLC stock?
LivaNova PLC's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (2.73%), Bank of New York Mellon Corp (1.10%), NWQ Investment Management Company LLC (1.04%), Wells Fargo & Company MN (0.82%), American Century Companies Inc. (0.80%) and New York State Common Retirement Fund (0.62%). Company insiders that own LivaNova PLC stock include Alfred J Novak, Daniel Jeffrey Moore, Hugh M Morrison, Jacques Gutedel, Sharon O'kane and Two SCA Equinox. View Institutional Ownership Trends for LivaNova PLC.
Who sold LivaNova PLC stock? Who is selling LivaNova PLC stock?
LivaNova PLC's stock was sold by a variety of institutional investors in the last quarter, including Third Avenue Management LLC, Janus Henderson Group PLC, Stifel Financial Corp, KBC Group NV, Investment Counselors of Maryland LLC, Epoch Investment Partners Inc., Allianz Asset Management GmbH and Rock Point Advisors LLC. Company insiders that have sold LivaNova PLC company stock in the last year include Alfred J Novak, Daniel Jeffrey Moore and Hugh M Morrison. View Insider Buying and Selling for LivaNova PLC.
Who bought LivaNova PLC stock? Who is buying LivaNova PLC stock?
LivaNova PLC's stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, American Century Companies Inc., NWQ Investment Management Company LLC, Hosking Partners LLP, New York State Common Retirement Fund, Fisher Asset Management LLC, Retirement Systems of Alabama and PEAK6 Investments L.P.. View Insider Buying and Selling for LivaNova PLC.
How do I buy LivaNova PLC stock?
Shares of LivaNova PLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is LivaNova PLC's stock price today?
One share of LivaNova PLC stock can currently be purchased for approximately $84.32.
How big of a company is LivaNova PLC?
LivaNova PLC has a market capitalization of $3.97 billion and generates $1.2139 billion in revenue each year. The company earns ($62,780,000.00) in net income (profit) each year or $3.75 on an earnings per share basis. LivaNova PLC employs 4,500 workers across the globe.
How can I contact LivaNova PLC?
LivaNova PLC's mailing address is 20 Eastbourne Terrace, LONDON, W2 6LG, United Kingdom. The company can be reached via phone at +44-20-37865275 or via email at firstname.lastname@example.org.
MarketBeat Community Rating for LivaNova PLC (NASDAQ LIVN)MarketBeat's community ratings are surveys of what our community members think about LivaNova PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for LivaNova PLC (NASDAQ:LIVN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Hold (Score: 2.43)|
|Consensus Price Target: ||$76.83 (8.88% downside)|
Consensus Price Target History for LivaNova PLC (NASDAQ:LIVN)
Analysts' Ratings History for LivaNova PLC (NASDAQ:LIVN)
(Data available from 11/19/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/14/2017||Canaccord Genuity||Reiterated Rating||Hold||$76.00||N/A|
|11/7/2017||BTIG Research||Reiterated Rating||Hold||N/A|
|11/3/2017||Piper Jaffray Companies||Reiterated Rating||Buy||$85.00||N/A|
|11/3/2017||Jefferies Group LLC||Boost Price Target||Buy||$80.00 -> $91.00||N/A|
|11/3/2017||Needham & Company LLC||Boost Price Target||Buy -> Buy||$83.00 -> $89.00||N/A|
|8/15/2017||WBB Securities||Downgrade||Hold -> Sell||$50.00||Low|
|8/11/2017||Berenberg Bank||Reiterated Rating||Buy||$70.00||Low|
|2/29/2016||Kepler Capital Markets||Boost Price Target||Hold||$63.00 -> $66.00||N/A|
Earnings History and Estimates Chart for LivaNova PLC (NASDAQ:LIVN)
Earnings History by Quarter for LivaNova PLC (NASDAQ LIVN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/7/2018|| || || || || || || || |
|11/2/2017||Q3 2017||$0.76||$0.93||$301.22 million||$309.70 million||View||N/A|
|8/9/2017||Q2 2017||$0.82||$1.01||$315.75 million||$321.40 million||View||Listen|
|3/1/2017||Q416||$0.79||$0.82||$301.45 million||$310.60 million||View||Listen|
|11/2/2016||Q316||$0.76||$0.78||$299.40 million||$295.30 million||View||N/A|
Earnings Estimates for LivaNova PLC (NASDAQ:LIVN)
2017 EPS Consensus Estimate: $1.46
2018 EPS Consensus Estimate: $3.70
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for LivaNova PLC (NASDAQ:LIVN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for LivaNova PLC (NASDAQ LIVN)
Insider Ownership Percentage: 0.28%
Institutional Ownership Percentage: 82.20%
Insider Trades by Quarter for LivaNova PLC (NASDAQ LIVN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/15/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$81.39||$81,390.00|| |
|10/16/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$74.58||$74,580.00|| |
|9/15/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$68.55||$68,550.00|| |
|8/15/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$60.76||$60,760.00|| |
|7/17/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$61.55||$61,550.00|| |
|6/15/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$60.80||$60,800.00|| |
|5/23/2017||Sharon O'kane||Director||Buy||1,000||$58.58||$58,580.00|| |
|5/22/2017||Alfred J Novak||Director||Sell||1,000||$58.49||$58,490.00|| |
|5/5/2017||Hugh M Morrison||Director||Sell||3,215||$55.89||$179,686.35|| |
|4/17/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$51.32||$51,320.00|| |
|3/15/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$50.21||$50,210.00|| |
|9/22/2016||Two S.C.A. Equinox||Major Shareholder||Sell||185,000||$61.54||$11,384,900.00|| |
|9/21/2016||Two S.C.A. Equinox||Major Shareholder||Sell||391,379||$60.69||$23,752,791.51|| |
|9/16/2016||Two S.C.A. Equinox||Major Shareholder||Sell||75,213||$59.86||$4,502,250.18|| |
|9/13/2016||Two S.C.A. Equinox||Major Shareholder||Sell||25,408||$60.02||$1,524,988.16|| |
|9/8/2016||Two S.C.A. Equinox||Major Shareholder||Sell||208,000||$60.52||$12,588,160.00|| |
|8/9/2016||Jacques Gutedel||Insider||Sell||4,000||$60.52||$242,080.00|| |
|5/24/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$50.07||$50,070.00|| |
|5/19/2016||Hugh M Morrison||Director||Sell||3,600||$48.00||$172,800.00|| |
|5/6/2016||Alfred J Novak||Director||Sell||4,000||$51.12||$204,480.00|| |
|4/15/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$54.81||$54,810.00|| |
|3/15/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$56.88||$56,880.00|| |
|2/16/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$56.88||$56,880.00|| |
|1/15/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$52.64||$52,640.00|| |
|12/15/2015||Daniel Jeffrey Moore||Director||Sell||2,500||$53.97||$134,925.00|| |
Latest Headlines for LivaNova PLC (NASDAQ LIVN)
|LivaNova PLC (LIVN) Director Sells $81,390.00 in Stock|
www.americanbankingnews.com - November 16 at 4:50 PM
|LivaNova PLC's (LIVN) Hold Rating Reaffirmed at Canaccord Genuity|
www.americanbankingnews.com - November 14 at 11:03 PM
|LivaNova to Present at the Piper Jaffray and Berenberg Conferences|
finance.yahoo.com - November 8 at 2:01 PM
|LivaNova PLC (LIVN) Receives Consensus Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - November 6 at 8:04 AM
|FY2017 Earnings Estimate for LivaNova PLC Issued By Jefferies Group (LIVN)|
www.americanbankingnews.com - November 6 at 4:36 AM
|LivaNova PLC (LIVN) Given New $89.00 Price Target at Needham & Company LLC|
www.americanbankingnews.com - November 5 at 8:56 PM
|Jefferies Group LLC Boosts LivaNova PLC (LIVN) Price Target to $91.00|
www.americanbankingnews.com - November 5 at 10:06 AM
|LivaNova PLC's (LIVN) "Buy" Rating Reiterated at Piper Jaffray Companies|
www.americanbankingnews.com - November 3 at 10:46 PM
|Livanova PLC to Host Earnings Call|
finance.yahoo.com - November 3 at 7:52 PM
|LivaNova PLC (LIVN) Raised to Buy at ValuEngine|
www.americanbankingnews.com - November 3 at 12:46 AM
|LivaNova PLC (LIVN) Issues Earnings Results|
www.americanbankingnews.com - November 2 at 6:44 PM
|Reviewing Nevro Corp. (NVRO) & LivaNova PLC (LIVN)|
www.americanbankingnews.com - November 2 at 3:18 PM
|LivaNova PLC (LIVN) Updates FY17 Earnings Guidance|
www.americanbankingnews.com - November 2 at 9:52 AM
|LivaNova Recognizes Epilepsy Awareness Month This November|
finance.yahoo.com - November 2 at 5:36 AM
|LivaNova PLC (LIVN) & Its Peers Critical Review|
www.americanbankingnews.com - October 31 at 1:06 PM
|LivaNova PLC (LIVN) Scheduled to Post Quarterly Earnings on Thursday|
www.americanbankingnews.com - October 26 at 5:00 AM
|ETFs with exposure to LivaNova Plc : October 20, 2017|
finance.yahoo.com - October 21 at 6:10 AM
|LivaNova PLC (LIVN) vs. Its Rivals Financial Contrast|
www.americanbankingnews.com - October 21 at 4:24 AM
|Daniel Jeffrey Moore Sells 1,000 Shares of LivaNova PLC (LIVN) Stock|
www.americanbankingnews.com - October 17 at 7:48 PM
|LivaNova PLC (LIVN) Given Average Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - October 12 at 6:58 AM
|ETFs with exposure to LivaNova Plc : October 9, 2017|
finance.yahoo.com - October 9 at 4:29 PM
|LivaNova Plc :LIVN-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017|
finance.yahoo.com - October 7 at 2:36 AM
|Head to Head Analysis: LivaNova PLC (LIVN) versus Its Competitors|
www.americanbankingnews.com - October 4 at 2:36 PM
|LivaNova and MicroPort Announce the Approval of Rega Pacemakers by the China Food and Drug Administration|
finance.yahoo.com - September 28 at 1:58 AM
|LivaNova Announces U.S. Launch of Optiflow Arterial Cannulae Family|
finance.yahoo.com - September 25 at 7:03 PM
|Head-To-Head Survey: LivaNova PLC (LIVN) versus CryoLife (CRY)|
www.americanbankingnews.com - September 25 at 2:36 PM
|LivaNova PLC (LIVN) Stock Rating Reaffirmed by Canaccord Genuity|
www.americanbankingnews.com - September 20 at 9:42 AM
|LivaNova PLC (LIVN) Director Daniel Jeffrey Moore Sells 1,000 Shares|
www.americanbankingnews.com - September 19 at 4:28 PM
|LivaNova PLC (LIVN) Receives Consensus Rating of "Hold" from Analysts|
www.americanbankingnews.com - September 17 at 9:02 AM
|LivaNova PLC (LIVN) Lifted to Buy at Needham & Company LLC|
www.americanbankingnews.com - September 16 at 8:26 PM
|LivaNova PLC (LIVN) PT Raised to $80.00|
www.americanbankingnews.com - September 15 at 2:34 PM
|LivaNova PLC (LIVN) Upgraded at Needham & Company LLC|
www.americanbankingnews.com - September 15 at 8:30 AM
|LivaNova Defines Strategic Outlook at Investor Day|
finance.yahoo.com - September 15 at 5:56 AM
|LivaNova to Explore Strategic Options for Cardiac Rhythm Management Business Franchise|
finance.yahoo.com - September 14 at 7:11 AM
|LivaNova PLC (LIVN) Now Covered by Analysts at Piper Jaffray Companies|
www.americanbankingnews.com - September 12 at 12:34 PM
|LivaNova Announces Publication of Literature Review Highlighting the Clinical Value and Safety of the Perceval Sutureless Valve for Aortic Valve Replacement|
finance.yahoo.com - September 11 at 10:33 PM
|Jefferies Group Comments on LivaNova PLC's Q3 2017 Earnings (LIVN)|
www.americanbankingnews.com - September 11 at 1:42 AM
|LivaNova PLC (LIVN) Coverage Initiated by Analysts at Jefferies Group LLC|
www.americanbankingnews.com - September 8 at 8:42 PM
|LivaNova Plc breached its 50 day moving average in a Bearish Manner : LIVN-US : August 29, 2017|
finance.yahoo.com - August 30 at 6:07 AM
|Analyzing LivaNova PLC (LIVN) and Align Technology (ALGN)|
www.americanbankingnews.com - August 24 at 10:26 PM
|LivaNova PLC (LIVN) Receives Average Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - August 23 at 9:16 AM
|Financial Review: LivaNova PLC (LIVN) & InspireMD (NSPR)|
www.americanbankingnews.com - August 20 at 2:28 PM
|LivaNova Plc breached its 50 day moving average in a Bearish Manner : LIVN-US : August 18, 2017|
finance.yahoo.com - August 18 at 8:44 PM
|Insider Selling: LivaNova PLC (LIVN) Director Sells 1,000 Shares of Stock|
www.americanbankingnews.com - August 17 at 10:24 AM
|LivaNova Plc – Value Analysis (NASDAQ:LIVN) : August 17, 2017|
finance.yahoo.com - August 17 at 1:52 AM
|LivaNova PLC (LIVN) Downgraded to "Sell" at WBB Securities|
www.americanbankingnews.com - August 15 at 11:20 AM
|LivaNova PLC (LIVN) Receives "Buy" Rating from Berenberg Bank|
www.americanbankingnews.com - August 12 at 5:42 PM
|See what the IHS Markit Score report has to say about LivaNova PLC.|
finance.yahoo.com - August 12 at 2:39 AM
|LivaNova PLC (NASDAQ:LIVN) Posts Earnings Results, Beats Expectations By $0.19 EPS|
www.americanbankingnews.com - August 11 at 11:46 PM
|LivaNova plc (LIVN) Tops Q2 EPS by 19c, Beats on Revenues; Reaffirms FY17 EPS Mid-Point Guidance Above Consensus|
www.streetinsider.com - August 10 at 2:26 AM
LivaNova PLC (NASDAQ LIVN) Chart for Sunday, November, 19, 2017